Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/New drug REM-422 shows 43% response rate in rare cancer trial with durable effects and good safety.
REMX
$76.66
-$2.48 -3.13%

New drug REM-422 shows 43% response rate in rare cancer trial with durable effects and good safety.

Company Fundamentals
21 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Remix Therapeutics announced positive Phase 1/2 trial results for REM-422, a novel oral MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma (ACC). The trial showed a 43% overall response rate at the recommended Phase 2 dose, with durable responses lasting over a year and a 100% disease control rate. REM-422 was well tolerated with mostly mild side effects. These promising results support further development of REM-422 as a potential treatment for ACC, a cancer with limited therapeutic options.

More News (REMX)

VanEck Rare Earth and Strategic Metals ETF (REMX) shows high volatility, rated hold amid market headwinds.

VanEck Rare Earth and Strategic Metals ETF (REMX) shows high volatility, rated hold amid market headwinds.

The VanEck Rare Earth and Strategic Metals ETF (REMX) provides exposure to 38 global companies in rare earth and strategic metals, with a notable focus on China. Despite a strong long-term outlook for rare earths, REMX currently faces challenges such...

Market News
Neutral
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App